Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Cough/Cold “Reverse Switch” Will Not Increase Safety – CHPA

This article was originally published in The Tan Sheet

Executive Summary

A potential "reverse switch" of pediatric cough/cold OTC drugs to prescription status would not address concerns about efficacy or misuse of the products, the Consumer Healthcare Products Association says
Advertisement

Related Content

Bionorica Steers U.S. Consumers To Natural Products Through Science
Bionorica Steers U.S. Consumers To Natural Products Through Science
U.K. To Move Kids’ Cough/Cold Drugs BTC, Redraws Age Recommendation
Firms Consult FDA, Add “Do Not Use” For Under 4 To Pediatric Cold Products
Calls For Cough/Cold Collaboration As FDA Inches Toward Rulemaking
FDA Call For Pediatric Cough/Cold Input Signals New Rule Is A Long Way Off
FDA Call For Pediatric Cough/Cold Input Signals New Rule Is A Long Way Off
National Survey Shows 1 In 10 Children Use Cough/Cold OTCs Each Week
Infant Cold Products Pulled; Waxman Looks For More OTC Risks
FDA Review Of Children’s Cough/Cold OTCs Has Broader Implications

Topics

Advertisement
UsernamePublicRestriction

Register

PS102439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel